Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multiple ascending-dose study of inhaled ARCT-032 in adults with cystic fibrosis
MOH_2026-05-20_015839Phase 2Not yet recruiting
- Sponsor
- Arcturus Therapeutics
- Start
- May 2025
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARCT-032 in cystic fibrosis (CF), sponsored by Arcturus Therapeutics. Planned start May 2025; status: not yet recruiting.
02
Drugs
ARCT-032
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2026-05-20_015839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-20_015839.